Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A personalized oral immunotherapy (OIT) regimen developed at Stanford University for the treatment of multiple food allergies. The intervention involves the gradual administration of escalating doses of specific food proteins (such as peanut, egg, milk, tree nut, and seed proteins) to which a patient is clinically reactive. The goal is to induce desensitization by modulating the immune system, specifically targeting dendritic cells and reducing IgE-mediated allergic responses. This approach allows for the simultaneous treatment of multiple food allergies using natural food proteins as the active biologic agents. The treatment is tailored to each patient's specific allergy profile based on skin tests or specific IgE levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multi-allergen oral immunotherapy (Stanford University).